EUCTR2016-002580-34-ES进行中（未招募）1 期
A double blind placebo controlled study to evaluate the effect ofbexagliflozin tablets on hemoglobin A1c in patients with type 2diabetes mellitus and moderate renal impairment
Theracos Sub, LLC0 个研究点目标入组 300 人开始时间: 2016年8月11日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Men or non-pregnant women = 20 years of age. Women of childbearing potential must agree to use contraception during the entire study to avoid any possible pregnancy.
- •Females who are surgically sterile (hysterectomy, oophorectomy) or postmenopausal (absence of menses greater than 12 months and age > 45 years) are eligible if they test negative on the urine pregnancy test.
- •2. Subjects with a diagnosis of T2DM with an HbA1c between 7.0 and 10.5% (inclusive) at the time of screening.
- •3. Subjects who are treatment naïve or are treated with a stable regimen of anti-diabetic medications. At the time of screening, the doses and frequency of all anti-diabetic medications must have been stable for 8 weeks.
- •4. Subjects who have an estimated glomerular filtration rate (eGFR) = 30 and
- •< 60 mL/min/1.73 m2 at 2 time points: screening (V1), and 1 additional time point between 1 and 12 monhs of screening (may be obtained from available medical records).
- •The eGFR will be calculated by the MDRD equation.
- •5. Subjects who have a body mass index (BMI) = 45 kg/m2 (inclusive)
- •6. Subjects who taking stable doses of medications for hypertension or hyperlipidemia for at least 30 days prior to randomization
- •7. Subjects who have stable eGFR between the historic value and day of screening (no more than 20% change in eGFR).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •1. Diagnosis of type 1 diabetes mellitus or maturity–onset diabetes of the young (MODY)
- •2. Hemoglobinopathy that affects HbA1c measurement
- •3. Frequent symptomatic hypoglycemia (greater than one episode per week on average)
- •4. Genitourinary tract infection within 6 weeks of screening or history of = 3 genitourinary infections requiring treatment within the last 6 months
- •5. Cancer, active or in remission for < 3 years (Non-melanoma skin cancer or basal cell carcinoma or carcinoma in situ of the cervix will not be grounds for exclusion)
- •6. History of alcohol or illicit drug abuse in the past 2 years
- •7. Evidence of abnormal liver function tests (total bilirubin or alkaline phosphatase > 1.5 x upper limit of normal (ULN) with the exception of isolated Gilbert's syndrome); or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 x ULN
- •8. History of MI, stroke or hospitalization for heart failure, or hospitalization for unstable angina in the prior 3 months
- •9. Evidence of NYHA class IV heart failure at screening or randomization
- •10. Currently or within 3 months of taking an SGLT2 inhibitor from screening (Appendix 5)
- •11. Any condition, disease, disorder, or clinically relevant laboratory abnormality that, in the opinion of the PI, would jeopardize the subject's appropriate participation in this study or obscure the effects of treatment
- •12. Women who are pregnant or breastfeeding
- •13. Patients who are receiving renal replacement therapy (peritoneal or hemodialysis) or who have undergone renal transplantation
- •14. Corrected serum calcium < 8 mg/dL (Appendix 4) at screening (V1) or randomization (V3)
- •15. Uncontrolled hypertension (systolic blood pressure > 170 or diastolic blood pressure> 110)
- •16. Currently participating in another interventional trial or receiving treatment with an investigational drug within 30 days or 7 half-lives of screening, whichever is longer
- •17. Previous treatment with bexagliflozin or EGT0001474
- •18. Missing 1 or more doses of the study drug during the run-in period
- •19. Fasting blood glucose value during the run-in period = 250 mg/dL (13.9 mmol/L) associated with severe clinical signs or symptoms of hyperglycemia
- •20. Any episode of symptomatic hypoglycemia during the run-in period in which symptoms are severe
- •21. Subjects who are unable to read and write in their native language
- •22. Subjects who are unable to comprehend and willing to provide written informed consent in accordance with institutional and regulatory guidelines
研究者
相似试验
进行中（未招募）
1 期
A clinical trial in patients with type II diabetes with increased risk of cardiovascular events (incidents that may cause damage to the heart muscle), to study how well a person’s diabetes is controlled over a 2-3 month period with bexagliflozin, by measuring blood sugar levels using a HbA1c test, and to determine safety by assessing occurrence of cardiovascular events.Type II diabetesMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2015-001760-19-NLTheracos Sub, LLC1,650
已完成
3 期
A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse eventsType 2 diabetes and increased risk of cardiovascular adverse events100192801001842410003216NL-OMON47856Theracos Sub, LLC132
进行中（未招募）
1 期
A clinical trial in patients with type II diabetes with increased risk of cardiovascular events (incidents that may cause damage to the heart muscle), to study how well a person’s diabetes is controlled over a 2-3 month period with bexagliflozin, by measuring blood sugar levels using a HbA1c test, and to determine safety by assessing occurrence of cardiovascular events.Type II diabetesMedDRA version: 20.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 100000004861EUCTR2015-001760-19-DKTheracos Sub, LLC1,650
进行中（未招募）
1 期
A clinical trial in patients with type II diabetes with increased risk of cardiovascular events (incidents that may cause damage to the heart muscle), to study how well a person’s diabetes is controlled over a 2-3 month period with bexagliflozin, by measuring blood sugar levels using a HbA1c test, and to determine safety by assessing occurrence of cardiovascular events.Type II diabetesMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2015-001760-19-PLTheracos Sub, LLC1,650
进行中（未招募）
1 期
A clinical trial in patients with type II diabetes with increased risk of cardiovascular events (incidents that may cause damage to the heart muscle), to study how well a person’s diabetes is controlled over a 2-3 month period with bexagliflozin, by measuring blood sugar levels using a HbA1c test, and to determine safety by assessing occurrence of cardiovascular events.Type II diabetesMedDRA version: 18.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2015-001760-19-DETheracos Sub, LLC1,700